Investigation agent 3
Phase 2Small molecule
Investigation agent 3 is one of 46 small molecule programs targeting Follicular Lymphoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Follicular Lymphoma
#DrugCompanyPhaseTrials
1Gazyva
RocheApproved
Oncovin
Eli LillyApproved
Adriamycin
PfizerApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Rituxan
RochePhase 3
Treanda
AAzurity Pharmaceuticals
Approved
Thalomid
Bristol-Myers SquibbApproved
Trexall
Jazz PharmaceuticalsApproved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Fludara
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Investigation agent 3. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Birmingham